DE69416705T2 - 1H-Indol-3-essigsäure-hydrazid als sPLA2 Inhibitoren - Google Patents

1H-Indol-3-essigsäure-hydrazid als sPLA2 Inhibitoren

Info

Publication number
DE69416705T2
DE69416705T2 DE69416705T DE69416705T DE69416705T2 DE 69416705 T2 DE69416705 T2 DE 69416705T2 DE 69416705 T DE69416705 T DE 69416705T DE 69416705 T DE69416705 T DE 69416705T DE 69416705 T2 DE69416705 T2 DE 69416705T2
Authority
DE
Germany
Prior art keywords
indole
acetic acid
acid hydrazide
spla2 inhibitors
spla2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69416705T
Other languages
English (en)
Other versions
DE69416705D1 (de
Inventor
Nicholas James Bach
Robert Delane Dillard
Susan Elizabeth Draheim
Robert Bell Hermann
Richard Walter Schevitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69416705D1 publication Critical patent/DE69416705D1/de
Application granted granted Critical
Publication of DE69416705T2 publication Critical patent/DE69416705T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DE69416705T 1993-04-16 1994-04-14 1H-Indol-3-essigsäure-hydrazid als sPLA2 Inhibitoren Expired - Fee Related DE69416705T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4860893A 1993-04-16 1993-04-16

Publications (2)

Publication Number Publication Date
DE69416705D1 DE69416705D1 (de) 1999-04-08
DE69416705T2 true DE69416705T2 (de) 1999-07-29

Family

ID=21955471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69416705T Expired - Fee Related DE69416705T2 (de) 1993-04-16 1994-04-14 1H-Indol-3-essigsäure-hydrazid als sPLA2 Inhibitoren

Country Status (27)

Country Link
US (1) US5578634A (de)
EP (1) EP0620214B1 (de)
JP (1) JP3621128B2 (de)
KR (1) KR100330816B1 (de)
CN (1) CN1067986C (de)
AT (1) ATE177081T1 (de)
AU (1) AU669782B2 (de)
BR (1) BR9401484A (de)
CA (1) CA2121321A1 (de)
CO (1) CO4230091A1 (de)
CZ (1) CZ289791B6 (de)
DE (1) DE69416705T2 (de)
DK (1) DK0620214T3 (de)
ES (1) ES2128510T3 (de)
FI (1) FI941766A (de)
GR (1) GR3029689T3 (de)
HU (1) HU220221B (de)
IL (1) IL109309A (de)
NO (1) NO300210B1 (de)
NZ (1) NZ260299A (de)
PL (1) PL179472B1 (de)
RU (1) RU2127725C1 (de)
SI (1) SI0620214T1 (de)
TW (1) TW306914B (de)
UA (1) UA40575C2 (de)
YU (1) YU20094A (de)
ZA (1) ZA942614B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1067054C (zh) * 1994-04-01 2001-06-13 伊莱利利公司 1H-吲哚-3-乙醛酰胺sPLA2抑制剂
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
KR100482268B1 (ko) * 1996-08-01 2005-04-14 메르클레 게엠베하 세포질 포스포리파제 ａ2의 저해제로서의 아실피롤디카르복실산
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
TR199900956T2 (xx) * 1996-10-30 1999-07-21 Eli Lilly And Company S�bstit�e edilmi� trisiklik bile�imler.
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
US6713645B1 (en) * 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
WO1998037069A1 (fr) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Derives d'acide indoldicarboxylique
CN1310706A (zh) * 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
KR20010042307A (ko) 1998-03-31 2001-05-25 시오노 요시히코 피롤로[1,2-ａ]피라진 ｓＰＬＡ2 억제제
ID23219A (id) * 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
EP1085021A4 (de) 1998-05-21 2003-01-08 Shionogi & Co PYRROLO[1,2-B]PYRIDAZIN-DERIVATE MIT sPLA 2? HEMMENDEM EFFEKT
WO2000007590A1 (en) 1998-08-03 2000-02-17 Eli Lilly And Company INDOLE sPLA2 INHIBITORS
EP1100493A4 (de) * 1998-08-03 2001-10-24 Lilly Co Eli INHIBITOREN DER sPLA 2? DES INDOLTYPS
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
ATE329619T1 (de) 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
US6448284B1 (en) 1998-12-22 2002-09-10 Eli Lilly And Company Substituted tricyclics
AU2373600A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Novel spla2 inhibitors
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (fr) 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001267824A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
EP1349834A2 (de) 2000-12-18 2003-10-08 Eli Lilly And Company Cycloalkyl kondensierte [g]-indol verbindungen als spla2-inhibitoren zur behandlung von entzündungskrankheiten
TWI314457B (de) * 2001-03-19 2009-09-11 Shionogi & Co
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
KR20130023381A (ko) 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
US7531568B2 (en) 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
WO2006102126A2 (en) * 2005-03-18 2006-09-28 Duke University Inhibitors of isoprenylcysteine carboxyl methyltransferase
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
WO2007056275A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2890677B1 (de) * 2012-08-30 2017-11-15 Chong Kun Dang Pharmaceutical Corp. N-acylhydrazonderivate für einen selektiven t-zell-inhibitor und ein arzneimittel gegen anti-lymphoid-malignität
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2890223A (en) * 1956-03-22 1959-06-09 Research Corp 1-benzyl, 2-methyl, 5-methoxy tryptamine
US3242193A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3196162A (en) * 1961-03-13 1965-07-20 Merck & Co Inc Indolyl aliphatic acids
US3242162A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3271416A (en) * 1961-10-24 1966-09-06 Merck & Co Inc Indolyl aliphatic acids
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Also Published As

Publication number Publication date
TW306914B (de) 1997-06-01
US5578634A (en) 1996-11-26
CA2121321A1 (en) 1994-10-17
EP0620214A1 (de) 1994-10-19
YU20094A (sh) 1997-03-07
IL109309A (en) 2000-06-29
HU220221B (hu) 2001-11-28
SI0620214T1 (en) 1999-08-31
CZ289791B6 (cs) 2002-04-17
EP0620214B1 (de) 1999-03-03
HU9401058D0 (en) 1994-08-29
GR3029689T3 (en) 1999-06-30
AU5948694A (en) 1994-10-20
CN1067986C (zh) 2001-07-04
IL109309A0 (en) 1994-07-31
BR9401484A (pt) 1994-11-22
JPH0710838A (ja) 1995-01-13
DE69416705D1 (de) 1999-04-08
DK0620214T3 (da) 1999-09-27
RU2127725C1 (ru) 1999-03-20
HUT70205A (en) 1995-09-28
CZ89494A3 (en) 1994-11-16
UA40575C2 (uk) 2001-08-15
JP3621128B2 (ja) 2005-02-16
ES2128510T3 (es) 1999-05-16
NZ260299A (en) 1996-03-26
KR100330816B1 (ko) 2002-11-01
FI941766A0 (fi) 1994-04-15
CO4230091A1 (es) 1995-10-19
ATE177081T1 (de) 1999-03-15
NO941360D0 (no) 1994-04-15
FI941766A (fi) 1994-10-17
CN1098714A (zh) 1995-02-15
PL179472B1 (en) 2000-09-29
AU669782B2 (en) 1996-06-20
NO300210B1 (no) 1997-04-28
NO941360L (no) 1994-10-17
ZA942614B (en) 1995-10-16

Similar Documents

Publication Publication Date Title
DE69416705D1 (de) 1H-Indol-3-essigsäure-hydrazid als sPLA2 Inhibitoren
FI941767A (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
ATE220394T1 (de) 1h-indol-3-glyoxylamid spla2 inhibitoren
ATE203744T1 (de) Naphthyl-acetamide als spla2-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee